325 related articles for article (PubMed ID: 32737988)
1. NKp30 - A prospective target for new cancer immunotherapy strategies.
Pinheiro PF; Justino GC; Marques MM
Br J Pharmacol; 2020 Oct; 177(20):4563-4580. PubMed ID: 32737988
[TBL] [Abstract][Full Text] [Related]
2. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
3. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
[TBL] [Abstract][Full Text] [Related]
4. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
Zhang T; Wu MR; Sentman CL
J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
[TBL] [Abstract][Full Text] [Related]
5. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
6. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
7. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
8. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
[TBL] [Abstract][Full Text] [Related]
9. B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
Phillips M; Romeo F; Bitsaktsis C; Sabatino D
Biopolymers; 2016 Sep; 106(5):658-72. PubMed ID: 27216712
[TBL] [Abstract][Full Text] [Related]
10. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.
Li Y; Wang Q; Mariuzza RA
J Exp Med; 2011 Apr; 208(4):703-14. PubMed ID: 21422170
[TBL] [Abstract][Full Text] [Related]
11. Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.
Herrmann J; Berberich H; Hartmann J; Beyer S; Davies K; Koch J
J Biol Chem; 2014 Jan; 289(2):765-77. PubMed ID: 24275655
[TBL] [Abstract][Full Text] [Related]
12. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.
Cao G; Wang J; Zheng X; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Dec; 290(50):29964-73. PubMed ID: 26472927
[TBL] [Abstract][Full Text] [Related]
13. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.
Butler SE; Brog RA; Chang CH; Sentman CL; Huang YH; Ackerman ME
Cancer Immunol Immunother; 2022 Jan; 71(1):165-176. PubMed ID: 34046711
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
[TBL] [Abstract][Full Text] [Related]
15. A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells.
Binici J; Hartmann J; Herrmann J; Schreiber C; Beyer S; Güler G; Vogel V; Tumulka F; Abele R; Mäntele W; Koch J
J Biol Chem; 2013 Nov; 288(48):34295-303. PubMed ID: 24133212
[TBL] [Abstract][Full Text] [Related]
16. The potential of B7-H6 as a therapeutic target in cancer immunotherapy.
Mohammadi A; Najafi S; Amini M; Mansoori B; Baghbanzadeh A; Hoheisel JD; Baradaran B
Life Sci; 2022 Sep; 304():120709. PubMed ID: 35697295
[TBL] [Abstract][Full Text] [Related]
17. PET Imaging of the Natural Killer Cell Activation Receptor NKp30.
Shaffer TM; Aalipour A; Schürch CM; Gambhir SS
J Nucl Med; 2020 Sep; 61(9):1348-1354. PubMed ID: 32532927
[TBL] [Abstract][Full Text] [Related]
18. B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.
Lucar O; Sadjo Diallo M; Bayard C; Samri A; Tarantino N; Debré P; Thiébaut R; Brun-Vézinet F; Matheron S; Cheynier R; Vieillard V;
AIDS; 2019 Jan; 33(1):23-32. PubMed ID: 30325780
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site.
Joyce MG; Tran P; Zhuravleva MA; Jaw J; Colonna M; Sun PD
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6223-8. PubMed ID: 21444796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
